Kirby McInerney | <span >Fennec Pharmaceuticals Inc. Investigation</span >
This links to the home page
Cases
PRACTICE AREAS

Fennec Pharmaceuticals Inc. Investigation


The law firm of  Kirby McInerney LLP is investigating potential claims against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC). The investigation concerns whether Fennec and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On August 11, 2020, Fennec issued a press release announcing receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for the Company’s PEDMARK product, a formulation of sodium thiosulfate for intravenous administration for the ototoxicity associated with cisplatin chemotherapy. The press release advised investors that “[a]ccording to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.  The Company plans to request a Type A meeting to discuss the issues and other matters that were described in the CRL pertaining to the steps required for the resubmission of the NDA for PEDMARK.”
On this news, Fennec’s stock price fell $3.51 per share, or 34.51%, to close at $6.66 per share on August 11, 2020.
 
If you purchased or otherwise acquired Fennec securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.  

Fennec Pharmaceuticals Inc. Investor Contact Form